The global pingueculum drugs market is projected to register a substantial CAGR of 7.3% in the forecast period of 2022 to 2029. The new market report contains data for the historic year 2020, the base year of calculation is 2021, and the forecast period is 2022 to 2029.
Market Segmentation:
Global Pingueculum Drugs Market, By Treatment (Artificial Tears /Topical Lubricants, Steroid Eye Drops, Non-steroidal Anti Inflammatory Drops, and Others), Formulation Type (Eye Drops, Eye Ointments, and Others), Mode of Purchase (Prescription, Over the Counter), Drug Type (Branded, Generics), Population Type (Geriatric, Adults), End User (Hospitals, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others), Country (U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Netherlands, Russia, Switzerland, Turkey, Austria, Norway, Hungary, Lithuania, Ireland, Poland, Luxembourg, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Brazil, Argentina, Peru, Rest of South America, Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, Rest of the Middle East and Africa) Industry Trends and Forecast to 2029.
Some of the major factors contributing to the growth of the global pingueculum drugs market are:
Rise in the prevalence of pingueculum disease around the globe
Rise in the UV exposure to the individuals due to ozone defect casing pingueculum more frequently
Market Players:
Some of the major players operating in the global pingueculum drugs market are:
AbbVie Inc.
Amneal Pharmaceuticals LLC.
Spectra Vision Care
SAGER PHARMA
Maya Biotech Private Limited
Novartis AG
Akorn Operating Company LLC
Thea Laboratories
OASIS Medical, Inc.
Similasan Corporation
Bausch & Lomb Incorporated
Prestige Consumer Healthcare, Inc.
Alcon Inc.
Wellona Pharma
Johnson & Johnson Vision Care, Inc.
EYERIS VISIONCARE Pvt. Ltd.
Sylentis
Zydus Group
Bayer AG
Santen Pharmaceutical Co., Ltd.
TABLE OF CONTENTS
1 INTRODUCTION 44
- 1.1 OBJECTIVES OF THE STUDY 44
- 1.2 MARKET DEFINITION 44
- 1.3 OVERVIEW OF THE GLOBAL PINGUECULUM DRUGS MARKET 44
- 1.4 CURRENCY AND PRICING 46
- 1.5 LIMITATIONS 46
- 1.6 MARKETS COVERED 47
2 GLOBAL PINGUECULUM DRUGS MARKET: SEGMENTATION 49
- 2.1 MARKETS COVERED 49
- 2.2 GEOGRAPHICAL SCOPE 50
- 2.3 YEARS CONSIDERED FOR THE STUDY 51
- 2.4 CURRENCY AND PRICING 51
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 52
- 2.6 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55
- 2.7 MULTIVARIATE MODELLING 56
- 2.8 TREATMENT LIFELINE CURVE 56
- 2.9 DBMR MARKET POSITION GRID 57
- 2.10 VENDOR SHARE ANALYSIS 59
- 2.11 MARKET END-USER COVERAGE GRID 60
- 2.12 SECONDARY SOURCES 61
- 2.13 ASSUMPTIONS 61
3 EXECUTIVE SUMMARY 62
4 PREMIUM INSIGHTS 66
- 4.1 EPIDERMIOLOGY 68
- 4.2 PESTEL ANALYSIS 69
- 4.3 PORTER'S FIVE FORCES 70
- 4.4 PIPELINE ANALYSIS FOR THE GLOBAL PINGUECULUM DRUGS MARKET 71
- 4.5 INDUSTRIAL INSIGHTS: 72
- 4.6 CONCLUSION: 72
5 GLOBAL PINGUECULUM DRUGS MARKET: REGULATIONS 73
6 MARKET OVERVIEW 76
- 6.1 DRIVERS 78
- 6.1.1 RISING PREVALENCE OF PINGUECELA DISORDERS AND OCULAR PAINS 78
- 6.1.2 RISE IN THE CHRONIC UV RADIATION EXPOSURE DUE TO OZONE DEFECT 78
- 6.1.3 INCREASING AWARENESS AMONG PEOPLE FOR EYE-RELATED DISEASES 79
- 6.1.4 RISING OPHTHALMIC EMERGENCIES IN THE GERIATRIC PATIENT 80
- 6.2 RESTRAINTS 80
- 6.2.1 STRINGENT RULES & REGULATIONS 80
- 6.2.2 LACK OF HEALTHCARE FACILITIES FOR EYE TREATMENT 81
- 6.3 OPPORTUNITIES 82
- 6.3.1 INITIATIVES AND PLANS TO LESSEN THE PREVALENCE OF EYE ILLNESSES 82
- 6.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES 82
- 6.3.3 INCREASE IN HEALTHCARE SPENDING AND ACCESSIBLE INCOME 83
- 6.4 CHALLENGES 84
- 6.4.1 ADVERSE EFFECTS OF STEROID EYE DROPS 84
- 6.4.2 LACK OF SKILLED OPHTHALMOLOGISTS 85
7 GLOBAL PINGUECULUM DRUGS MARKET, BY TREATMENT 86
- 7.1 OVERVIEW 87
- 7.2 ARTIFICIAL TEARS/TOPICAL LUBRICANTS 90
- 7.2.1 DEMULCENT 90
- 7.2.2 EMOLLIENTS 90
- 7.3 STEROID EYE DROPS 91
- 7.3.1 KETONE STEROIDS 92
- 7.3.1.1 PREDNISOLONE 92
- 7.3.1.2 DEXAMETHASONE 92
- 7.3.1.3 FLUROMETHOLONE 92
- 7.3.1.4 MEDRYSONE 92
- 7.3.1.5 RIMEXOLONE 92
- 7.3.1.6 OTHERS 92
- 7.3.2 ESTER STEROID (LOTERPREDNOL) 93
- 7.4 NON-STEROIDAL ANTI-INFLAMMATORY DROPS 93
- 7.5 OTHERS 93
8 GLOBAL PINGUECULUM DRUGS MARKET, BY FORMULATION 94
- 8.1 OVERVIEW 95
- 8.2 EYE DROPS 98
- 8.2.1 EYE DROPS WITH PRESERVATIVES 98
- 8.2.2 PRESERVATIVE-FREE EYE DROPS 98
- 8.3 EYE OINTMENTS 99
- 8.3.1 WITH PRESERVATIVES 99
- 8.3.2 PRESERVATIVE-FREE 99
- 8.3.3 OTHERS 99
- 8.4 OTHERS 100
9 GLOBAL PINGUECULUM DRUGS MARKET, MODE OF PURCHASE 101
- 9.1 OVERVIEW 102
- 9.2 PRESCRIPTION 105
- 9.3 OVER THE COUNTER (OTC) 105
10 GLOBAL PINGUECULUM DRUGS MARKET, BY DRUGS TYPE 106
- 10.1 OVERVIEW 107
- 10.2 BRANDED 110
- 10.3 GENERICS 110
11 GLOBAL PINGUECULUM DRUGS MARKET, BY POPULATION TYPE 111
- 11.1 OVERVIEW 112
- 11.2 GERIATRIC 115
- 11.2.1 MALE 115
- 11.2.2 FEMALE 115
- 11.3 ADULTS 116
- 11.3.1 MALE 116
- 11.3.2 FEMALE 116
12 GLOBAL PINGUECULUM DRUGS MARKET, BY END USER 117
- 12.1 OVERVIEW 118
- 12.2 HOSPITALS 121
- 12.3 SPECIALTY CLINICS 121
- 12.4 HOME HEALTHCARE 122
- 12.5 OTHERS 122
13 GLOBAL PINGUECULUM DRUGS MARKET, BY DISTRIBUTION CHANNEL 123
- 13.1 OVERVIEW 124
- 13.2 RETAIL PHARMACIES 127
- 13.3 HOSPITAL PHARMACIES 127
- 13.4 ONLINE PHARMACIES 128
- 13.5 OTHERS 128
14 GLOBAL PINGUECULUM DRUGS MARKET, BY REGION 129
- 14.1 OVERVIEW 130
- 14.2 ASIA-PACIFIC 136
- 14.2.1 CHINA 146
- 14.2.2 INDIA 150
- 14.2.3 JAPAN 154
- 14.2.4 INDONESIA 158
- 14.2.5 SOUTH KOREA 162
- 14.2.6 AUSTRALIA 166
- 14.2.7 THAILAND 170
- 14.2.8 VIETNAM 174
- 14.2.9 PHILIPPINES 178
- 14.2.10 MALAYSIA 182
- 14.2.11 SINGAPORE 186
- 14.2.12 REST OF ASIA- PACIFIC 190
- 14.3 EUROPE 191
- 14.3.1 SPAIN 200
- 14.3.2 RUSSIA 204
- 14.3.3 TURKEY 208
- 14.3.4 GERMANY 212
- 14.3.5 ITALY 216
- 14.3.6 U.K. 220
- 14.3.7 FRANCE 224
- 14.3.8 HUNGARY 228
- 14.3.9 AUSTRIA 232
- 14.3.10 SWITZERLAND 236
- 14.3.11 NETHERLANDS 240
- 14.3.12 POLAND 244
- 14.3.13 IRELAND 248
- 14.3.14 NORWAY 252
- 14.3.15 LITHUANIA 256
- 14.3.16 REST OF EUROPE 260
- 14.4 NORTH AMERICA 261
- 14.4.1 U.S. 270
- 14.4.2 MEXICO 274
- 14.4.3 CANADA 278
- 14.5 SOUTH AMERICA 282
- 14.5.1 BRAZIL 291
- 14.5.2 ARGENTINA 295
- 14.5.3 PERU 299
- 14.5.4 REST OF SOUTH AMERICA 303
- 14.6 MIDDLE EAST AND AFRICA 304
- 14.6.1 SOUTH AFRICA 313
- 14.6.2 EGYPT 317
- 14.6.3 ISRAEL 321
- 14.6.4 U.A.E 325
- 14.6.5 SAUDI ARABIA 329
- 14.6.6 KUWAIT 333
- 14.6.7 REST OF MIDDLE EAST AND AFRICA 337
15 GLOBAL PINGUECULUM DRUGS MARKET: COMPANY LANDSCAPE 338
- 15.1 COMPANY SHARE ANALYSIS: GLOBAL 338
- 15.2 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 339
- 15.3 COMPANY SHARE ANALYSIS: NORTH AMERICA 340
- 15.4 COMPANY SHARE ANALYSIS: EUROPE 341
16 SWOT ANALYSIS 342
17 COMPANY PROFILE 343
- 17.1 ALCON INC. 343
- 17.1.1 COMPANY SNAPSHOT 343
- 17.1.2 REVENUE ANALYSIS 343
- 17.1.3 COMPANY SHARE ANALYSIS 344
- 17.1.4 PRODUCT PORTFOLIO 344
- 17.1.5 RECENT DEVELOPMENT 344
- 17.2 ABBVIE INC. 345
- 17.2.1 COMPANY SNAPSHOT 345
- 17.2.2 REVENUE ANALYSIS 345
- 17.2.3 COMPANY SHARE ANALYSIS 346
- 17.2.4 PRODUCT PORTFOLIO 346
- 17.2.5 RECENT DEVELOPMENT 347
- 17.3 BAUSCH & LOMB INCORPORATED 348
- 17.3.1 COMPANY SNAPSHOT 348
- 17.3.2 REVENUE ANALYSIS 348
- 17.3.3 COMPANY SHARE ANALYSIS 349
- 17.3.4 PRODUCT PORTFOLIO 349
- 17.3.5 RECENT DEVELOPMENT 350
- 17.4 BAYER AG 351
- 17.4.1 COMPANY SNAPSHOT 351
- 17.4.2 REVENUE ANALYSIS 351
- 17.4.3 COMPANY SHARE ANALYSIS 352
- 17.4.4 PRODUCT PORTFOLIO 352
- 17.4.5 RECENT DEVELOPMENTS 352
- 17.5 JOHNSON & JOHNSON VISION CARE, INC. 353
- 17.5.1 COMPANY SNAPSHOT 353
- 17.5.2 REVENUE ANALYSIS 353
- 17.5.3 COMPANY SHARE ANALYSIS 354
- 17.5.4 PRODUCT PORTFOLIO 354
- 17.5.5 RECENT DEVELOPMENT 354
- 17.6 AKORN OPERATING COMPANY LLC 355
- 17.6.1 COMPANY SNAPSHOT 355
- 17.6.2 . PRODUCT PORTFOLIO 355
- 17.6.3 RECENT DEVELOPMENT 355
- 17.7 AMNEAL PHARMACEUTICALS LLC. 356
- 17.7.1 COMPANY SNAPSHOT 356
- 17.7.2 REVENUE ANALYSIS 356
- 17.7.3 PRODUCT PORTFOLIO 357
- 17.7.4 RECENT DEVELOPMENTS 357
- 17.8 EYERIS VISIONCARE PVT. LTD. 358
- 17.8.1 COMPANY SNAPSHOT 358
- 17.8.2 PRODUCT PORTFOLIO 358
- 17.8.3 RECENT DEVELOPMENTS 359
- 17.9 LABORATOIRES THEA 360
- 17.9.1 COMPANY SNAPSHOT 360
- 17.9.2 PRODUCT PORTFOLIO 360
- 17.9.3 RECENT DEVELOPMENT 361
- 17.10 MAYA BIOTECH PRIVATE LIMITED 362
- 17.10.1 COMPANY SNAPSHOT 362
- 17.10.2 PRODUCT PORTFOLIO 362
- 17.10.3 RECENT DEVELOPMENTS 363
- 17.11 NOVARTIS AG 364
- 17.11.1 COMPANY SNAPSHOT 364
- 17.11.2 REVENUE ANALYSIS 364
- 17.11.3 PRODUCT PORTFOLIO 365
- 17.11.4 RECENT DEVELOPMENT 365
- 17.12 OASIS MEDICAL, INC. 366
- 17.12.1 COMPANY SNAPSHOT 366
- 17.12.2 PRODUCT PORTFOLIO 366
- 17.12.3 RECENT DEVELOPMENT 366
- 17.13 PRESTIGE CONSUMER HEALTHCARE, INC. 367
- 17.13.1 COMPANY SNAPSHOT 367
- 17.13.2 PRODUCT PORTFOLIO 368
- 17.13.3 RECENT DEVELOPMENT 368
- 17.14 SAGER PHARMA 369
- 17.14.1 COMPANY SNAPSHOT 369
- 17.14.2 PRODUCT PORTFOLIO 369
- 17.14.3 RECENT DEVELOPMENTS 369
- 17.15 SANTEN PHARMACEUTICAL CO., LTD. 370
- 17.15.1 COMPANY SNAPSHOT 370
- 17.15.2 REVENUE ANALYSIS 370
- 17.15.3 PRODUCT PORTFOLIO 371
- 17.15.4 RECENT DEVELOPMENTS 371
- 17.16 SIMILASAN CORPORATION 372
- 17.16.1 COMPANY SNAPSHOT 372
- 17.16.2 PRODUCT PORTFOLIO 372
- 17.16.3 RECENT DEVELOPMENTS 372
- 17.17 SPECTRA VISION CARE 373
- 17.17.1 COMPANY SNAPSHOT 373
- 17.17.2 PRODUCT PORTFOLIO 373
- 17.17.3 RECENT DEVELOPMENTS 374
- 17.18 SYLENTIS 375
- 17.18.1 COMPANY SNAPSHOT 375
- 17.18.2 PRODUCT PORTFOLIO 375
- 17.18.3 RECENT DEVELOPMENTS 375
- 17.19 WELLONA PHARMA 376
- 17.19.1 COMPANY SNAPSHOT 376
- 17.19.2 PRODUCT PORTFOLIO 376
- 17.19.3 RECENT DEVELOPMENTS 376
- 17.20 ZYDUS GROUP 377
- 17.20.1 COMPANY SNAPSHOT 377
- 17.20.2 REVENUE ANALYSIS 377
- 17.20.3 PRODUCT PORTFOLIO 378
- 17.20.4 RECENT DEVELOPMENTS 378
18 QUESTIONNAIRE 379
19 RELATED REPORTS 383